Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioRestorative Therapies (BRTX) Profit After Tax (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Profit After Tax for 15 consecutive years, with -$3.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Profit After Tax fell 178.38% year-over-year to -$3.0 million, compared with a TTM value of -$12.7 million through Sep 2025, down 31.34%, and an annual FY2024 reading of -$9.0 million, up 13.81% over the prior year.
  • Profit After Tax was -$3.0 million for Q3 2025 at BioRestorative Therapies, down from -$2.7 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $4.8 million in Q3 2023 and bottomed at -$20.4 million in Q4 2021.
  • Average Profit After Tax over 5 years is -$5.0 million, with a median of -$4.1 million recorded in 2021.
  • The sharpest move saw Profit After Tax crashed 400.35% in 2021, then surged 202.41% in 2023.
  • Year by year, Profit After Tax stood at -$20.4 million in 2021, then skyrocketed by 86.92% to -$2.7 million in 2022, then rose by 13.66% to -$2.3 million in 2023, then rose by 28.99% to -$1.6 million in 2024, then crashed by 85.7% to -$3.0 million in 2025.
  • Business Quant data shows Profit After Tax for BRTX at -$3.0 million in Q3 2025, -$2.7 million in Q2 2025, and -$5.3 million in Q1 2025.